Login / Signup

Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model.

Brittany L BunchKrithika N KodumudiEllen ScottJennifer MorseAmy Mackay WeberAnders E BerglundShari Pilon-ThomasJoseph Markowitz
Published in: Cancer immunology, immunotherapy : CII (2020)
Emm55 is a bacterial gene derived from Streptococcus pyogenes (S. pyogenes) that was cloned into a plasmid DNA vaccine (pAc/emm55). In this study, we investigated the anti-tumor efficacy of pAc/emm55 in a B16 murine melanoma model. Intralesional (IL) injections of pAc/emm55 significantly delayed tumor growth compared to the pAc/Empty group. There was a significant increase in the CD8+ T cells infiltrating into the tumors after pAc/emm55 treatment compared to the control group. In addition, we observed that IL injection of pAc/emm55 increased antigen-specific T cell infiltration into tumors. Depletion of CD4+ or CD8+ T cells abrogated the anti-tumor effect of pAc/emm55. Combination treatment of IL injection of pAc/emm55 with anti-PD-1 antibody significantly delayed tumor growth compared to either monotherapy. pAc/emm55 treatment combined with PD-1 blockade enhanced anti-tumor immune response and improved systemic anti-tumor immunity. Together, these strategies may lead to improvements in the treatment of patients with melanoma.
Keyphrases
  • immune response
  • combination therapy
  • randomized controlled trial
  • clinical trial
  • dendritic cells
  • dna methylation
  • crispr cas
  • study protocol
  • inflammatory response
  • circulating tumor
  • nk cells